KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biolife Solutions (BLFS) Short term Debt (2019 - 2025)

Biolife Solutions (BLFS) has disclosed Short term Debt for 7 consecutive years, with $5.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Short term Debt fell 54.34% to $5.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.0 million, a 54.34% decrease, with the full-year FY2025 number at $5.0 million, down 54.34% from a year prior.
  • Short term Debt was $5.0 million for Q4 2025 at Biolife Solutions, down from $7.5 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $12.2 million in Q3 2024 to a low of $52000.0 in Q3 2023.
  • A 5-year average of $5.0 million and a median of $3.5 million in 2021 define the central range for Short term Debt.
  • Peak YoY movement for Short term Debt: crashed 97.48% in 2023, then surged 23421.15% in 2024.
  • Biolife Solutions' Short term Debt stood at $862000.0 in 2021, then soared by 148.03% to $2.1 million in 2022, then skyrocketed by 193.97% to $6.3 million in 2023, then skyrocketed by 74.11% to $10.9 million in 2024, then crashed by 54.34% to $5.0 million in 2025.
  • Per Business Quant, the three most recent readings for BLFS's Short term Debt are $5.0 million (Q4 2025), $7.5 million (Q3 2025), and $10.1 million (Q2 2025).